Schering-Plough (SGP) Files Patent Infringement Suit Against GeoPharma (GORX)
More News related to GORX
- CORRECTION -- GeoPharma Announces Fiscal Year 2009 Fourth Quarter and Year End Results
- GeoPharma Announces Fiscal Year 2009 Fourth Quarter and Year End Results
- GeoPharma Announces Fiscal Year 2009 Year End Results Release Date and Conference Call
- GeoPharma (GORX) Announces Strategic Restructuring Plan
- GeoPharma (GORX) Adds India, Nepal, Bangladesh, Sri Lanka and South Korea as New Distribution Channels for Mucotrol(TM)
More News related to SGP
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
- Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings
- SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus
GeoPharma, Inc. (Nasdaq: GORX) announced that Schering-Plough (NYSE: SGP), has filed a lawsuit against the Company and its wholly owned subsidiary, Belcher Pharmaceuticals, Inc. in the United States District Court, District of New Jersey (No. 3:06-cv-04715-MLC-TJB), alleging patent infringement related to Belcher's filing for a generic version of Clarinex Desloratadine 5 mg tablets.
According to the complaint, the other defendants are alleged to have filed their ANDA's and Paragraph IV certifications on the same day as Belcher, June 21, 2006. Schering Plough markets Clarinex (R) for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, chronic idiopathic urticaria. According to Schering-Plough, U.S. sales of Clarinex for 2005 were $325 million.
Related Categories
FDAStocks Mentioned
-0.04
+2.32Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
